AmerisourceBergen Corp

These names were recently added to the Morningstar Wide Moat Focus Index.

It continues to inflict pain on drug manufacturers and distributors.

We review the changes to the Morningstar Wide Moat Focus Index during the latest reconstitution and reveal the least-expensive names.

Five types of opioid-related shareholder resolutions are currently on ballots.

Plus, the 10 cheapest names in the index today.

We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended April 12.

All three companies still trade at 4 stars, however.

More than 50 stocks derive their wide moats from just one source. Is that a problem?

Its core operations will be needed no matter how market dynamics shift.

The pharma distributor has a solid foundation and a bright outlook, in our opinion.

These 10 undervalued Morningstar US Dividend Growth Index constituents are cash-rich businesses with sustainable and growing payouts.

We believe companies with moats from switching costs and intangible assets are less vulnerable.

We analyze earnings reports, discuss charitable donations, and look at winners and losers in this week's Investing Insights podcast.

A combination of Walgreens and drug distributor AmerisourceBergen would be fraught with valuation and operational challenges, says Morningstar's Vishnu Lekraj.

A vertical integration would benefit the no-moat retail pharmacy more than the wide-moat drug distributor.

New competition may seem inevitable, but moats in the pharma supply chain exist for a reason.

These high-quality names are on sale.

Six good funds are hit with outflows, but three small good funds are seeing inflows.

While there's no telling if their short-term momentum will continue, these stocks' long-term prospects look bright.

We like its improving operational dynamics and less uncertain near-term environment.